Scarica l'app Stockscreener
77.70
0.30%
-0.23
Dopo l'orario di chiusura:
78.83
1.13
+1.45%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché BBIO Giù?
Forum
Previsione
Bridgebio Pharma Inc Borsa (BBIO) Ultime notizie
BridgeBio Pharma(BBIO.US) Officer Sells US$5.97 Million in Common Stock - Moomoo
BridgeBio Pharma CEO Sells $2.98M in Stock - National Today
BridgeBio Pharma CEO Kumar sells $5.9m in BBIO stock - Investing.com
BridgeBio (BBIO) CEO-linked family trusts sell 80,000 shares under 10b5-1 plan - Stock Titan
Dip Buying: Will BridgeBio Pharma Inc benefit from government policyMarket Performance Summary & Weekly High Return Opportunities - baoquankhu1.vn
Assessing BridgeBio Pharma (BBIO) Valuation After Key ATTR-CM And LGMD2I/R9 Milestones - simplywall.st
BridgeBio Pharma Inc (NASDAQ:BBIO) Shows High Technical and Setup Ratings Ahead of Potential Breakout - ChartMill
BBIO (BridgeBio Pharma) PE Ratio : At Loss (As of Apr. 11, 2026) - GuruFocus
RBC Forecasts 35% Upside For BridgeBio Pharma Stock Following Attruby Drug Success - TIKR.com
RBC Capital initiates coverage of BridgeBio Pharma (BBIO) with outperform recommendation - MSN
BridgeBio Submits NDA for BBP-418 in LGMD2I/R9, Potentially the First Approved Therapy for Any Form of Limb-Girdle Muscular Dystrophy - NeurologyLive
120,000-share Form 144; BBIO insiders report 10b5-1 sales (BBIO) - Stock Titan
BridgeBio Pharma (BBIO) Receives Positive Analyst Coverage from RBC Capital | BBIO Stock News - GuruFocus
Assessing BridgeBio Pharma (BBIO) Valuation After Recent Share Price Strength And Late Stage Pipeline Focus - Yahoo Finance
RBC Initiates BridgeBio Pharma at Outperform, Speculative Risk With $100 Price Target - Moomoo
Barclays Maintains BridgeBio Pharma(BBIO.US) With Buy Rating, Maintains Target Price $157 - Moomoo
RBC Capital Initiates BridgeBio Pharma(BBIO.US) With Buy Rating, Announces Target Price $100 - Moomoo
RBC Capital initiates BridgeBio Pharma stock at Outperform with $100 target - Investing.com India
(BBIO) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily
Sentiment Watch: Should you buy the dip on BridgeBio Pharma Inc2026 Big Picture & AI Powered Market Entry Ideas - baoquankhu1.vn
Market Rankings: Will BridgeBio Pharma Inc benefit from green energy policies2026 Market Sentiment & Fast Entry High Yield Stock Tips - baoquankhu1.vn
BridgeBio Pharma, Inc. (BBIO) Stock forecasts - Yahoo Finance UK
BBIO Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Possible Bearish Signals With BridgeBio Pharma Insiders Disposing Stock - Moomoo
BridgeBio to present LGMD2I/R9 trial data at MDA conference By Investing.com - Investing.com India
Viking funds hold 6.1% of BridgeBio Pharma (NASDAQ: BBIO) - Stock Titan
BridgeBio to present LGMD2I/R9 trial data at MDA conference - Investing.com
BBOT SEC FilingsBridgeBio Oncology Therapeutics, Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Analysts Offer Insights on Healthcare Companies: Danaher (DHR), 60 Degrees Pharmaceuticals, Inc. (SXTP) and BridgeBio Pharma (BBIO) - The Globe and Mail
Bond Watch: Is BridgeBio Pharma Inc stock a value trapEarnings Trend Report & Step-by-Step Swing Trade Plans - baoquankhu1.vn
Allspring Global Investments Holdings LLC Has $77.78 Million Stock Holdings in BridgeBio Pharma, Inc. $BBIO - MarketBeat
BridgeBio Pharma, Inc. (NASDAQ:BBIO) Receives Consensus Recommendation of "Moderate Buy" from Brokerages - marketbeat.com
Sentiment Review: Will BridgeBio Pharma Inc benefit from green energy policies2026 Biggest Moves & Low Volatility Stock Recommendations - baoquankhu1.vn
Mizuho Lifts PT on BridgeBio Pharma (BBIO) to $106 From $91 – Here’s Why - Insider Monkey
H.C. Wainwright Maintains BridgeBio Pharma(BBIO.US) With Buy Rating, Maintains Target Price $100 - Moomoo
Bridgebio asks FDA to approve potential 1st treatment for LGMD2i - Muscular Dystrophy News
Piper Sandler Maintains BridgeBio Pharma(BBIO.US) With Buy Rating, Maintains Target Price $111 - Moomoo
BridgeBio's rare-disease pipeline sparks growth buzz - MSN
INVESCO Small Cap Equity Fund's BridgeBio Pharma Inc(BBIO) Holding History - GuruFocus
Assenagon Asset Management S.A. Decreases Stock Position in BridgeBio Pharma, Inc. $BBIO - MarketBeat
BridgeBio submits NDA for oral BBP-418 to treat LGMD2I/R9 - Investing.com Australia
BridgeBio Files NDA for LGMD2I/R9 Oral Therapy - TipRanks
BridgeBio (BBIO) Shares Promising Long-Term Acoramidis Data at A - GuruFocus
BridgeBio (BBIO) Submits Application for New Muscular Dystrophy Treatment - GuruFocus
BridgeBio (NASDAQ: BBIO) files NDA for first potential LGMD2I/R9 treatment - stocktitan.net
BridgeBio reports sustained mortality benefits for acoramidis at 54 months By Investing.com - Investing.com Canada
BridgeBio Pharma Announces Sustained Clinical Benefits of Acoramidis in Long-Term ATTRibute-CM Trial - Quiver Quantitative
BridgeBio Pharma, Inc. Presents Long-Term Efficacy and Safety Data from the ATTRibute-CM Open-Label Extension Trial - marketscreener.com
Jefferies reiterates Buy on BridgeBio Pharma stock, $100 target By Investing.com - Investing.com Canada
BridgeBio submits NDA to FDA for BBP-418 for individuals living with LGMD2I/R9 - marketscreener.com
BridgeBio Submits NDA to FDA for BBP-418 for Individuals Living with LGMD2I/R9 - manilatimes.net
BridgeBio Pharma stock drops 3.97% as NDA filed with FDA for BBP-418 therapy - Traders Union
5 High Growth Healthcare Stocks to Buy Now - Insider Monkey
BridgeBio Pharma stock price forecast: mixed signals as BBIO retreats 3.97% toward key support - Traders Union
Will New Long-Term ATTRibute-CM Data on Acoramidis Shift BridgeBio Pharma's (BBIO) Narrative? - Yahoo Finance
2.69%
0.25%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):